Stock listing

NASDAQ:LTGO Latigo Biotherapeutics, Inc. Stock

Home listing (NASDAQ) of Latigo Biotherapeutics, Inc.

Follow Latigo Biotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LTGO

$13.00 USD -0.31 (-2.3%)

Close on Nov 20, 2026

Past 3 months -27.8% · daily closes, Aug 6, 2026 – Nov 20, 2026, adjusted for splits
Day range
$11.91 – $13.35 USDNov 20, 2026
Volume
267,166 sharesNov 20, 2026
Market cap
$861.9M USDAt the close on Nov 20, 2026 · price × 66.30M shares outstanding
Traded on an average day
$5.42M USDMedian day 234,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LTGO · Home$13.00 USD-0.31 (-2.3%)267,166$13.22$13.35$11.91$13.31Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LTGO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$13.00-0.31-2.3%$13.22$13.35$11.91267,166
$13.31-0.45-3.3%$14.00$14.23$13.21209,071
$13.76+1.16+9.2%$12.56$14.11$12.56661,609
$12.60-0.51-3.9%$12.99$13.27$12.32505,045
$13.11+0.18+1.4%$12.99$13.22$11.75406,524
$12.93-0.59-4.4%$13.35$13.59$12.20167,664
$13.52+0.19+1.4%$13.36$14.35$13.36198,821
$13.33-0.02-0.1%$13.23$14.00$12.96780,387
$13.35+0.75+6.0%$12.59$13.90$12.59326,381
$12.60-0.41-3.2%$13.18$15.95$12.11555,445
$13.01-1.03-7.3%$13.21$13.29$10.45424,277
$14.04-0.53-3.6%$14.87$15.00$13.96155,949
$14.57+1.06+7.8%$13.53$15.10$13.53244,858
$13.51-0.44-3.2%$15.02$15.02$13.29289,064
$13.95-1.59-10.2%$15.65$15.70$13.66216,168
$15.54-0.29-1.8%$16.00$16.74$15.44141,658
$15.83+0.62+4.1%$15.27$16.06$15.14187,418
$15.21-0.05-0.3%$15.33$15.86$15.01164,098
$15.26+0.24+1.6%$15.14$15.49$14.24165,322
$15.02-1.55-9.4%$16.51$16.55$14.84146,000
$16.57+0.23+1.4%$16.36$17.67$16.19119,400
$16.34+1.09+7.1%$15.45$16.78$15.18173,800
$15.25+0.95+6.6%$14.37$15.56$14.25147,800
$14.30+0.30+2.1%$14.04$14.52$13.54283,800
$14.00-0.76-5.1%$14.96$15.11$13.85207,400
$14.76+0.76+5.4%$14.09$14.90$13.50242,900
$14.00-1.71-10.9%$15.74$15.74$13.85220,600
$15.71-0.31-1.9%$16.12$16.51$15.56346,800
$16.02+0.02+0.1%$16.00$16.56$15.80133,000
$16.00+1.21+8.2%$14.84$16.08$14.61184,200
$14.79-0.73-4.7%$15.52$15.52$14.60265,100
$15.52-0.74-4.6%$16.22$16.35$15.27241,500
$16.26-0.37-2.2%$16.77$16.89$16.06544,500
$16.63+0.73+4.6%$16.06$17.07$15.87590,000
$15.90-0.79-4.7%$16.80$16.90$15.67276,600
$16.69-0.01-0.1%$16.70$17.55$16.48436,700
$16.70-1.40-7.7%$18.04$18.32$16.25532,600
$18.10+0.62+3.5%$17.33$18.50$17.30955,200
$17.48+0.33+1.9%$17.15$17.84$16.19260,300
$17.15-0.61-3.4%$17.81$18.26$17.00275,700
$17.76-2.21-11.1%$19.73$20.54$17.67340,700
$19.97-0.85-4.1%$20.77$20.79$19.71214,600
$20.82-0.29-1.4%$21.11$21.33$20.01418,800
$21.11-1.44-6.4%$22.80$23.11$21.00411,400
$22.55-1.38-5.8%$24.18$24.80$22.211,488,200
$23.93+0.87+3.8%$23.14$24.80$23.09431,000
$23.06+0.05+0.2%$23.00$24.33$22.75438,900
$23.01+0.37+1.6%$22.50$24.75$22.48221,400
$22.64+0.49+2.2%$22.33$23.79$22.33164,800
$22.15+0.61+2.8%$21.76$23.22$21.50178,700
$21.54-1.26-5.5%$22.78$23.17$21.28177,200
$22.80-0.93-3.9%$23.72$23.98$22.44190,400
$23.73+0.69+3.0%$23.25$24.40$22.21326,800
$23.04+0.56+2.5%$22.68$23.57$22.02226,400
$22.48+0.71+3.3%$21.99$23.41$21.82229,300
$21.77-0.49-2.2%$22.58$23.85$21.40163,200
$22.26+0.24+1.1%$22.50$23.77$21.26286,600
$22.02-2.21-9.1%$24.41$24.70$21.75155,000
$24.23-0.77-3.1%$25.21$25.81$24.23217,700
$25.00+0.87+3.6%$24.15$25.93$24.08235,500
$24.13+1.56+6.9%$22.64$24.79$22.37137,900
$22.57+0.57+2.6%$22.07$22.76$21.74142,800
$22.00-0.37-1.7%$22.62$25.00$21.42234,100
$22.37+0.97+4.5%$21.52$22.90$20.64197,200
$21.40+0.46+2.2%$20.75$21.71$20.5282,700
Ticker
NASDAQ:LTGO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Latigo Biotherapeutics, Inc. news

Latigo Biotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 6 in all · newest Nov 5, 2026 · oldest 2026
Decks
1 deck · latest September 2026

Where Latigo Biotherapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LTGO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LTGOBOATSUnited StatesUSD

Valuation

Price/book 2.2× against a median of 2.5×: 6th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$460.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Latigo Biotherapeutics, Inc. · NASDAQ:LTGOUS$861.9MUS$460.7Mn/an/an/a2.2×n/a0.0×n/a
Metis TechBio Co., Ltd. Class H · HKEX:7666US$918.2MUS$486.7Mn/a222×n/a2.0×−373.2%0.0×n/a
InventisBio, Co., Ltd. Class A · SSE:688382US$899.5MUS$714.3Mn/a67.0×n/a4.6×−533.7%0.0×n/a
InnoCare Pharma Ltd. Class A · SSE:688428US$896.7M−US$209.5M9.3×−0.6×−2.3×0.8×27.1%0.1×n/a
Bio-Thera Solutions, Ltd. Class A · SSE:688177US$880.1MUS$926.3Mn/a5.9×n/a137×−42.0%14.3×n/a
Immatics N.V. · NASDAQ:IMTXUS$878.3MUS$375.4Mn/a7.9×n/a1.8×−534.1%0.0×1.40
Suzhou Ribo Life Science Co. Ltd. Class H · HKEX:6938US$875.5MUS$580.0Mn/a26.0×n/a3.4×−187.2%0.2×n/a
Aktis Oncology, Inc. · NASDAQ:AKTSUS$868.0MUS$385.9Mn/a31.2×n/a1.9×−706.8%0.0×1.21
Pharming Group NV · EURONEXT:PHARMUS$840.1MUS$766.3M34.4×2.0×19.8×2.9×6.3%0.4×n/a
Corvus Pharmaceuticals, Inc. · NASDAQ:CRVSUS$815.7MUS$613.4Mn/an/an/a3.9×n/a0.0×1.64
Odyssey Therapeutics, Inc. · NASDAQ:ODTXUS$815.2MUS$512.7Mn/an/an/a2.2×n/a0.1×1.11
Median of the othersUS$876.9MUS$546.3M21.9×16.9×8.7×2.5×−280.2%0.1×1.31

Forecasts

4 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
52.25 USD · Analysts' mean
EPS, year to Dec 2026
-2.71 · 3 analysts

Team and board

Officers

OfficerRole
Todd Smithpresident and chief executive officer, Director
Neha KrishnamohanChief Financial Officer and Chief Business Officer
Ada KumarVice President, Medical Affairs
Anil ChhettryVice President, Chemistry, Manufacturing and Controls
Becky BaggettVice President, Clinical Operations
Ben VaughnVice President, Biostatistics
Bryan MoyerSenior Vice President, Discovery
Caroline DoughertyVice President, Corporate Development
Cynthia VoongVice President, Clinical Operations
Holly CarlisleVice President, Translational Science
Julia ChapmanSenior Vice President, Operations
Mike KaufmanVice President, Chemistry
Naomi LowySenior Vice President, Global Regulatory Affairs
Polina GermanSenior Vice President, Clinical Pharmacology and Translational
Sabrina NiederVice President, Corporate Controller
Tim ClarkVice President, Government Affairs
Beth SeidenbergFounding Managing Director, Westlake BioPartners
Kevin RaidySenior Managing Director, Blue Owl Capital
Neil SinglaChief Medical Officer

Board

DirectorRole
Timothy P. WalbertChair, Board of Directors
Jim TananbaumDirector
Sara BonsteinIndependent Director
Todd Smithpresident and chief executive officer, Director

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−7.3%
Q2 2026Sep 3, 2026 · After close+2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck42 slidesSeptember 2026

Open Decks

IPO

Priced at US$18.00 a share on Aug 6, 2026.

Price
US$18.00 a share
Shares offered
19,200,000 shares of common stock
Offering size
US$345.6 million
Underwriters' option
Up to 2,880,000 more shares
Listing
LTGO on the Nasdaq Global Select Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, Guggenheim Securities · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMar 27, 2026
Filed publiclyJul 17, 2026
Amended twiceNewest Aug 4, 2026
Shares registered with an exchangeAug 4, 2026
Declared effective by the SECAug 6, 2026
Final prospectus, with the priceAug 7, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Aug 7, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development99.5M56.8M
Selling, general and administrative10.9M6.67M
Operating income-110.4M-63.5M
Depreciation and amortization249.0K244.0K
EBITDA-110.1M-63.2M
Income before tax-109.2M-61.2M
Net income-109.2M-61.2M
Earnings per share, basic-1.81-1.02

Balance sheet

LineFY2025FY2024
Cash and equivalents69.4M17.9M
Current assets73.8M21.2M
Total assets75.5M22.9M
Accounts payable5.01M7.07M
Current liabilities18.4M14.4M
Total liabilities307.2M152.5M
Shareholders' equity-231.7M-129.6M
Shares outstanding60.2M60.2M

Cash flow

LineFY2025FY2024
Cash from operations-97.6M-51.0M
Capital spending-136.0K-72.0K
Free cash flow-97.7M-51.0M
Cash from financing149.5M607.0K
Change in cash51.8M-50.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2026Big-stake noticeSEC
10-Q · Quarterly reportSep 3, 2026Quarterly reportSEC
All 49 filings
FilingDateTypeFiled with
8-K · Current reportSep 3, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 18, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 10, 2026Offer documentSEC
8-K · Current reportAug 10, 2026Current reportSEC
424B4 · ProspectusAug 7, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 7, 2026Other filingsSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringAug 6, 2026Offer documentSEC
CERT · Exchange's certificate of listingAug 6, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 4, 2026Other filingsSEC
S-1/A · Registration statement, amendedAug 3, 2026Offer documentSEC
S-1/A · Registration statement, amendedAug 3, 2026Offer documentSEC
S-1 · Registration statementJul 17, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJun 5, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMay 15, 2026Offer documentSEC
DRS · Draft registration statementMar 27, 2026Offer documentSEC
DFeb 13, 2025Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Latigo Biotherapeutics, Inc.’s releases · as of Sep 1, 2026

Common shares
66,299,347
Fully diluted
66,299,347

Fully diluted

LineSharesAs of
Common shares66,299,347Sep 1, 2026

Share count over time

CountShares
Sep 1, 202666,299,347

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
5AM Venture Management, LLC7.33M11.0%US$122MNewNov 16, 2026
Ra Capital Management, L.P.5.3M8.0%US$88.6MNewNov 16, 2026
Deep Track Capital, LP4.41M6.6%US$73.6MNewNov 16, 2026
Blue Owl Capital Holdings LP3.6M5.4%US$60.1MNewNov 13, 2026
Foresite Capital Management V, LLC3.56M5.4%US$59.5MNewNov 16, 2026
Fidelity2.88M4.3%US$48.1MNewNov 10, 2026
Foresite Capital Management VI LLC2.2M3.3%US$36.8MNewNov 16, 2026
Cormorant Asset Management, LP1.82M2.7%US$30.3MNewNov 16, 2026
Orbimed Advisors LLC1.68M2.5%US$28MNewNov 16, 2026
Vanguard1M1.5%US$16.7MNewNov 13, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
abrdn936K1.4%US$15.6MNewNov 10, 2026
Farallon Capital Management, L.L.C.850K1.3%US$14.2MNewNov 16, 2026
T. Rowe Price812K1.2%US$13.6MNewNov 16, 2026
Rtw Investments, LP700K1.1%US$11.7MNewNov 16, 2026
Sanofi673K1.0%US$11.2MNewNov 5, 2026
Rock Springs Capital Management LP654K0.99%US$10.9MNewNov 16, 2026
Balyasny Asset Management L.P.336K0.51%US$5.62MNewNov 16, 2026
Saturn V Capital Management LP300K0.45%US$5.02MNewNov 16, 2026
UBS293K0.44%US$4.9MNewNov 10, 2026
BlackRock292K0.44%US$4.88MNewNov 13, 2026
Affinity Asset Advisors, LLC250K0.38%US$4.17MNewNov 13, 2026
Geode Capital220K0.33%US$3.68MNewNov 6, 2026
Sphera Funds Management LTD.192K0.29%US$3.21MNewNov 16, 2026
Marshall Wace, LLP184K0.28%US$3.08MNewNov 13, 2026
Eversept Partners, LP173K0.26%US$2.89MNewNov 16, 2026
Woodline Partners LP140K0.21%US$2.34MNewNov 16, 2026
Schwab124K0.19%US$2.08MNewNov 16, 2026
Citadel101K0.15%US$1.69MNewNov 16, 2026
Superstring Capital Management LP88,1780.13%US$1.47MNewNov 16, 2026
Millennium83,2030.13%US$1.39MNewNov 16, 2026
Ghisallo Capital Management LLC80,0000.12%US$1.34MNewNov 19, 2026
Seven Grand Managers, LLC65,0000.10%US$1.09MNewNov 16, 2026
TD60,5660.09%US$1.1MNewNov 13, 2026
Burkehill Global Management, LP50,0000.08%US$835KNewNov 16, 2026
Northern Trust43,1790.07%US$721KNewNov 16, 2026
Goldman Sachs37,4390.06%US$625KNewNov 16, 2026
Squarepoint Ops LLC35,1450.05%US$587KNewNov 9, 2026
Schonfeld Strategic Advisors LLC25,8960.04%US$432KNewNov 16, 2026
Crcm LP25,3860.04%US$424KNewNov 10, 2026
Landscape Capital Management, L.L.C.24,0930.04%US$402KNewNov 10, 2026
State Street23,7000.04%US$396KNewNov 12, 2026
Jump Financial, LLC20,5440.03%US$343KNewNov 13, 2026
Legal & General16,9530.03%US$282KNewNov 16, 2026
ExodusPoint Capital Management, LP14,8020.02%US$247KNewNov 16, 2026
Cambridge Investment Research Advisors, Inc.13,8880.02%US$232NewNov 2, 2026
XTX Topco Ltd13,2380.02%US$221KNewNov 16, 2026
Morgan Stanley9,1120.01%US$152KNewNov 13, 2026
Aster Capital Management (DIFC) Ltd8,7090.01%US$145KNewNov 12, 2026
Tower Research Capital LLC (TRC)3,679<0.01%US$61,439NewNov 16, 2026
Citigroup Inc1,168<0.01%US$19,506NewNov 4, 2026

This page holds 50 of 55 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Foresite Capital Fund VI LP
10% owner
Buy140,000USD 18.00US$2.52MAug 10, 2026
James B. Tananbaum
Director, 10% owner
Buy140,000USD 18.00US$2.52MAug 10, 2026

Big stakes

HolderStakeSharesDate
Dr. Beth C. Seidenberg19.90%13.2MSep 30, 2026
James B. Tananbaum14.50%9.18MAug 10, 2026
Kush Parmar11.00%7.33MSep 30, 2026
Ra Capital Management, L.P.8.40%5.3MAug 10, 2026
Deep Track Capital, LP7.03%4.45MAug 7, 2026
Blue Owl Capital Holdings LP5.43%3.6MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Timothy P. Walbert
Other companies: Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Sagimet Biosciences Inc. - Series A (Director · Since at least Apr 1, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past)
Chair, Board of Directors · Since at least Aug 6, 2026
Beth C Seidenberg
Other companies: Kyverna Therapeutics, Inc. (Director · Since at least Feb 7, 2024); Sagimet Biosciences Inc. - Series A (Director · Since at least Jul 13, 2023); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past)
Director · Since at least Aug 6, 2026
Jim Tananbaum
Other companies: Alumis Inc. (Director · Since at least Jun 27, 2024); Quantum-Si Incorporated (Director · Jun 10, 2021 – Jun 10, 2021 · Past); Pardes Biosciences Inc (President and CEO, Director · Feb 16, 2021 – Aug 31, 2023 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Disc Medicine, Inc. (Director · Aug 11, 2020 – Oct 4, 2021 · Past)
Director · Since at least Aug 6, 2026
Sara Bonstein
Other companies: Xilio Therapeutics, Inc. (Chair of the Board · Since at least Oct 21, 2021); Scpharmaceuticals Inc (Director · Since at least Jul 8, 2020); Insmed Incorporated (Chief Financial Officer · Since at least Jan 31, 2020); Advaxis Inc (Chief Financial Officer · Mar 31, 2014 – Mar 29, 2018 · Past)
Independent Director · Since at least Aug 6, 2026
Todd Smith
Other companies: Assertio Holdings, Inc. (Director, Pres & CEO, Director · May 20, 2020 – May 20, 2020 · Past); Egalet Corporation (President and CEO, Director · Oct 23, 2019 – May 20, 2020 · Past); IVERIC bio Inc (SVP & CCO · Oct 3, 2014 – Jan 2, 2015 · Past); Horizon Pharma PLC (EVP, Chief Commercial Officer · Jul 28, 2011 – Sep 19, 2014 · Past)
president and chief executive officer, Director · Since at least Aug 6, 2026
Beth Seidenberg
Other companies: Sagimet Biosciences Inc. - Series A (Lead Independent Director · Since at least Nov 4, 2026); Vera Therapeutics, Inc. (Founding Managing Director, Westlake Village BioPartners · Since at least Nov 4, 2026); Kyverna Therapeutics, Inc. (Independent Director · Since at least May 29, 2026)
Founding Managing Director, Westlake BioPartners · Since at least Aug 10, 2026
Neha Krishnamohan
Other companies: Artiva Biotherapeutics, Inc. (Chief Financial Officer · Since at least Jul 18, 2024); Arcutis Biotherapeutics, Inc. (Director · Since at least Sep 2, 2022); Kinnate Biopharma Inc (CHIEF FINANCIAL OFFICER · Jun 7, 2021 – Apr 3, 2024 · Past)
Chief Financial Officer and Chief Business Officer · Since at least Aug 6, 2026
Nima Farzan
Other companies: Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); Kinnate Biopharma Inc (CHIEF EXECUTIVE OFFICER, Director · Dec 2, 2020 – Apr 3, 2024 · Past)
President and CEO, Director · Since at least Aug 6, 2026
Ada KumarVice President, Medical Affairs · Since at least Nov 4, 2026
Anil ChhettryVice President, Chemistry, Manufacturing and Controls · Since at least Nov 4, 2026
All 24 people
PersonSeat
Becky BaggettVice President, Clinical Operations · Since at least Nov 4, 2026
Ben VaughnVice President, Biostatistics · Since at least Nov 4, 2026
Bryan MoyerSenior Vice President, Discovery · Since at least Nov 4, 2026
Caroline DoughertyVice President, Corporate Development · Since at least Nov 4, 2026
Cynthia VoongVice President, Clinical Operations · Since at least Nov 4, 2026
Holly CarlisleVice President, Translational Science · Since at least Nov 4, 2026
Julia ChapmanSenior Vice President, Operations · Since at least Nov 4, 2026
Kevin RaidySenior Managing Director, Blue Owl Capital · Since at least Aug 6, 2026
Mike KaufmanVice President, Chemistry · Since at least Nov 4, 2026
Naomi LowySenior Vice President, Global Regulatory Affairs · Since at least Nov 4, 2026
Neil SinglaChief Medical Officer · Since at least Aug 6, 2026
Polina GermanSenior Vice President, Clinical Pharmacology and Translational · Since at least Nov 4, 2026
Sabrina NiederVice President, Corporate Controller · Since at least Nov 4, 2026
Tim ClarkVice President, Government Affairs · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Latigo Biotherapeutics, Inc.